These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 15505611

  • 21. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M, Nilsson C, Hassan Z, Gungor T, Aschan J, Winiarski J, Hentschke P, Ringdén O, Eber S, Seger R, Ljungman P.
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
    Elhasid R, Krivoy N, Rowe JM, Sprecher E, Adler L, Elkin H, Efrati E.
    Pediatr Blood Cancer; 2010 Dec 01; 55(6):1172-9. PubMed ID: 20672371
    [Abstract] [Full Text] [Related]

  • 24. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.
    McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, Anasetti C, Risler L, Sultan D, Slattery JT.
    Bone Marrow Transplant; 2002 Aug 01; 30(3):167-73. PubMed ID: 12189535
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation.
    Zhang H, Graiser M, Hutcherson DA, Dada MO, McMillan S, Ali Z, Flowers CR, Waller EK.
    Biol Blood Marrow Transplant; 2012 Aug 01; 18(8):1287-94. PubMed ID: 22370160
    [Abstract] [Full Text] [Related]

  • 27. Re: intravenous versus oral busulfan--perhaps not as different as suggested.
    Slattery JT.
    Biol Blood Marrow Transplant; 2003 Apr 01; 9(4):282-4. PubMed ID: 12720221
    [No Abstract] [Full Text] [Related]

  • 28. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Dupuis LL, Sibbald C, Schechter T, Ansari M, Gassas A, Théorêt Y, Kassir N, Champagne MA, Doyle J.
    Biol Blood Marrow Transplant; 2008 May 01; 14(5):576-82. PubMed ID: 18410900
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Absence of veno-occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage.
    Clopés A, Sureda A, Sierra J, Queraltó JM, Broto A, Farré R, Moreno E, Brunet S, Martino R, Mangues MA.
    Eur J Haematol; 2006 Jul 01; 77(1):1-6. PubMed ID: 16573745
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
    Kangarloo SB, Naveed F, Ng ES, Chaudhry MA, Wu J, Bahlis NJ, Brown CB, Daly A, Duggan P, Geddes M, Quinlan D, Savoie ML, Shafey M, Stewart DA, Storek J, Yang M, Zacarias N, Yue P, Magliocco AM, Russell JA.
    Biol Blood Marrow Transplant; 2012 Feb 01; 18(2):295-301. PubMed ID: 21801704
    [Abstract] [Full Text] [Related]

  • 34. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ, Lee JW, Yu KS, Hong KT, Choi JY, Hong CR, Park KD, Shin HY, Song SH, Kang HJ, Lee H.
    Am J Hematol; 2017 Jul 01; 92(7):607-613. PubMed ID: 28370238
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
    Chan KW, Mullen CA, Worth LL, Choroszy M, Koontz S, Tran H, Slopis J.
    Bone Marrow Transplant; 2002 Jun 01; 29(12):963-5. PubMed ID: 12098063
    [Abstract] [Full Text] [Related]

  • 38. Association of busulfan area under the curve with veno-occlusive disease following BMT.
    Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R.
    Bone Marrow Transplant; 1996 Feb 01; 17(2):225-30. PubMed ID: 8640171
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G.
    Clin Cancer Res; 2011 Nov 01; 17(21):6867-77. PubMed ID: 21918171
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.